TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35323040
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of beta-lactam treatment
Study: 35323040
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of beta-lactam treatment
Study: 34990854
Drug: Onsite buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onsite buprenorphine treatment initiation
Study: 35240966
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 200 mg 3 times a day (600mg daily) plus conventional treatment
Study: 34487750
Drug: Saroglitazar 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar 2 mg
Study: 36731585
Drug: Saroglitazar 4
Normalized name: Saroglitazar 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar 4 mg
Study: 36576555
Drug: Placebo (Isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Isotonic saline solution)
Study: 34652335
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CT)
Study: 34435694
Drug: Crisaborole ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole ointment, 2% (both QD and BID)
Study: 35908682
Drug: Mechanical instrumentation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical instrumentation without adjunct photodynamic therapy (Control)
Study: 35908682
Drug: Mechanical instrumentation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical instrumentation without adjunct photodynamic therapy (Control) in Group 2
Study: 35908682
Drug: Mechanical instrumentation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical instrumentation with adjunct photodynamic therapy (PDT) in Group 2
Study: 32145440
Drug: Granulocyte‐Macrophage Colony
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte‐Macrophage Colony Stimulating Factor (GM‐CSF) 500 μg/day subcutaneously thrice weekly for three weeks, followed by a second administration after 3 months.
Study: 32145440
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections thrice weekly for three weeks, followed by matching placebo injections after 3 months.
Study: 32552264
Drug: Extended-release oral
Normalized name: Carbinoxamine Maleate Extended-Release Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oral milrinone
Study: 32838463
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (PI)
Study: 32317229
Drug: Nighttime hydrating
Normalized name: Flonase Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime hydrating eyelid gel (TDHA-AOX and HA), applied nightly to the upper and inner eyelids of the right eye for 2 weeks
Study: 36453001
Drug: Narrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative therapy
Study: 32975739
Drug: D‐Fe (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐Fe (1000 IU/day vitamin D3 plus 27 mg/day iron)
Study: 33827495
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (14 sessions of individual manual-based cognitive behavioral therapy and motivational interviewing (MOVE-I))
Study: 34047872
Drug: 2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHX gel
Study: 35550827
Drug: Treatment aimed
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment aimed at improving family communication
Study: 34147142
Drug: Imatinib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (800 mg loading dose on day 0 followed by 400 mg daily on days 1-9)
Study: 32598812
Drug: Enoxaparin followed
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin followed by warfarin (1 mg/kg every 12 hours for 7 days, then warfarin to maintain INR 2.0-3.0)
Study: 32598812
Drug: Rivaroxaban monotherapy
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban monotherapy (15 mg twice/day for 21 days, then 20 mg/day)
Study: 32372290
Drug: Empagliflozin 10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10/25 mg
Study: 34762373
Drug: Moxibustion combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion combined with basic treatment
Study: 33735709
Drug: Baclofen 75
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 75 mg/day
Study: 35435089
Drug: Capacitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive and resistive electric transfer (CRET) therapy for 15 minutes on lower back
Study: 35435089
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy for 15 minutes on lower back
Study: 35635717
Drug: SHR6390 150-mg
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 150-mg tablet under high-fat conditions
Study: 35635717
Drug: SHR6390 150-mg
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 150-mg tablet under fasting conditions
Study: 32193541
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (tCS)
Study: 33960445
Drug: Imepitoin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imepitoin (30 mg/kg BID)
Study: 34130339
Drug: Enteric-coated formulations
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated formulations of aspirin
Study: 35169373
Drug: Debridement, antibiotics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement, antibiotics, irrigation and retention of prosthesis (DAIR)
Study: 34161706
Drug: Azithromycin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1-g single dose)
Study: 36456992
Drug: Vildagliptin treatment
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin treatment
Study: 34134825
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI)‐enhanced parent‐teen behavior therapy
Study: 33063705
Drug: Subcutaneous autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous autologous serum therapy
Study: 33063705
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular autologous serum therapy
Study: 36451459
Drug: PN +
Normalized name: Penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PN + EN (supplemental parenteral nutrition)
Study: 32527290
Drug: Endotracheal surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal surfactant administration followed by low peak pressure ventilation (LPPSA)
Study: 34986284
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy plus eltrombopag (Group B)
Study: 34986284
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (Group A)
Study: 34554372
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg o.d.)
Study: 34554372
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg o.d.)
Study: 32462216
Drug: Surgical needs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical needs survey administered by surgeons
Study: 32046671
Drug: Motor-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor-based treatment consistent with current best practices in speech therapy (40% of participants)
Study: 32046671
Drug: Treatment incorporating
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment incorporating visual biofeedback (60% of participants)
Study: 33602279
Drug: Nicotine supplementation
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine supplementation (2 mg)
Study: 35502947
Drug: Topical Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cannabidiol (CBD)
Study: 35390457
Drug: Topical Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cannabidiol (CBD) + Essential Oil (EO)
Study: 34551471
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg IV)
Study: 35366811
Drug: Left lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left lateral position (Group L)
Study: 33581481
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly sessions
Study: 35428889
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 mcg daily)
Study: 35428889
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with teriparatide followed by denosumab
Study: 36229342
Drug: Intramuscular ChAdOx1
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ChAdOx1 nCoV-19
Study: 36229342
Drug: Intranasal ChAdOx1
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ChAdOx1 nCoV-19
Study: 33406103
Drug: Wilderness programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wilderness programs employing adventure therapy
Study: 32948350
Drug: Sugar absorption
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar absorption test on days 4, 7, and 14 postpartum
Study: 32032954
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Treatment (BMT)
Study: 35013427
Drug: Post-treatment control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment control (individuals who can stop ART without viral load rebound)
Study: 34506719
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (LT) twice a week for 2 weeks
Study: 34506719
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control (no treatment during the same period)
Study: 33065774
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care (no DAA therapy)
Study: 35350983
Drug: ESP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESP block with 2 mg/kg levobupivacaine
Study: 35350983
Drug: ESP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESP block with 2 mg/kg levobupivacaine and 5 μg/mL epinephrine
Study: 35350983
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L and LE)
Study: 36093566
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg selenium as selenium-enriched yeast
Study: 38215286
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg selenium as selenium-enriched yeast
Study: 36093566
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg selenium as selenium-enriched yeast
Study: 36093566
Drug: 100, 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100, 200, or 300 μg selenium as selenium-enriched yeast
Study: 35280833
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg daily for 5 days)
Study: 33874683
Drug: Ultrafiltration on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration on top of standard therapy (diuretics, cardiotonic, vasodilator) with furosemide (40 mg) given immediately and 24 hours after ultrafiltration.
Study: 33874683
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plan (diuretics, cardiotonic, vasodilator) without ultrafiltration.
Study: 35038956
Drug: Narrow-band intense
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band intense pulsed light (DPL) treatment at a wavelength of 500-600 nm, initiated 2 weeks post-surgery, given 3 times over a 4-week period.
Study: 36355827
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga intervention self-administered over six weeks using an audio recording file
Study: 32471423
Drug: Once-daily fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler
Study: 32471423
Drug: Twice-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Study: 32471423
Drug: Twice-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Study: 36483622
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose (LD)
Study: 35822553
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg once per day for 6 months
Study: 33045224
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily (15 mg for creatinine clearance <50 mL/min)
Study: 33045224
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin (target INR 2.0-3.0)
Study: 35449839
Drug: Low-frequency nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency nerve therapy device
Study: 35449839
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment methods (Control)
Study: 32122870
Drug: Aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100 mg tablet b.i.d and enzyme supplements 250 mg b.i.d for 6 weeks
Study: 32122870
Drug: Aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100 mg tablet b.i.d
Study: 35304704
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency defined as soluble transferrin receptor (sTfR) > 28.1 nmol/L
Study: 35304704
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency defined as ferritin < 45 µg/L
Study: 35304704
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency defined as ferritin < 30 µg/L
Study: 35304704
Drug: Incidence rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incidence rate (IR) for ferritin < 45 µg/L
Study: 33442660
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment benefit
Study: 32282418
Drug: BUP‐XR (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP‐XR (300 mg initial injection, followed by monthly doses of 300 mg or 100 mg)
Study: 35510087
Drug: Clozapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (up to 400 mg per day)
Study: 32270440
Drug: Imeglimin (IMEG)
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Imeglimin (DB12509)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Imeglimin (IMEG) 1500 mg twice daily with Metformin (MET) 850 mg twice daily
Study: 35470909
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3, 600,000 IU 5 days before surgery (Group B)
Study: 33179323
Drug: Fremanezumab quarterly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab quarterly (675 mg at baseline)
Study: 33179323
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly (675 mg at baseline; 225 mg at Weeks 4 and 8)
Study: 32273630
Drug: Abound (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abound (24 g) administered for 14 days through an enteral feeding tube
Study: 32583478
Drug: Integrative Cognitive‐Affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Cognitive‐Affective Therapy (ICAT‐BED)
Study: 35098531
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) N-acetylcysteine (NAC) in healthy volunteers with contrast
Study: 35098531
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) NAC in patients with CKD3 receiving contrast
Study: 35098531
Drug: Oral NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NAC in healthy volunteers
Study: 33004272
Drug: Oxaliplatin treatment
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin treatment < 2 months prior to EVA/PCD analysis
Study: 33809557
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied formulation containing components of natural moisturizing factor (NMF)
Study: 39624908
Drug: Subcutaneous ICD
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous ICD (S-ICD)
Study: 33044367
Drug: FEN (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEN (300 mg·d)
Study: 33772303
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (GH) injections (0.050 mg/kg/day) for 12 months
Study: 33772303
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (GH) injections
Study: 34972770
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (individual cognitive behavioural therapy)
Study: 35449368
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olanzapine plus standard triple antiemetic therapy (aprepitant, tropisetron, dexamethasone)
Study: 35449368
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olanzapine plus tropisetron and dexamethasone (omitting aprepitant)
Study: 33355079
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (Group A): omeprazole, amoxicillin, clarithromycin, and bismuth subcitrate for 2 weeks.
Study: 34935724
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of damask rose 40% and lavender 10% essential oils
Study: 33121289
Drug: 0.5 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/d melatonin plus 30 minutes of 10,000 lux bright light therapy (BLT)
Study: 33601849
Drug: Anti-Toxoplasma antibodies
Normalized name: Toxoplasma gondii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Toxoplasma antibodies (IgM) testing
Study: 33601849
Drug: Avidity test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avidity test for IgG antibodies
Study: 34849690
Drug: Local gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local gentamicin treatment (collagenous carriers containing gentamicin left between sternal halves during sternal refixation)
Study: 33198568
Drug: Acupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (twice a week for 4 weeks + conventional therapy)
Study: 32658385
Drug: Hyperinsufflation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsufflation therapy (15 minutes twice daily using a cough assist device over 12 months)
Study: 32658385
Drug: Hyperinsufflation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsufflation therapy
Study: 34151671
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP) from the first day of the cycle to five days before starting ovarian stimulation
Study: 34151671
Drug: 2 mg/12
Normalized name: Kapvay, 0.2 mg/12 hr oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/12 hours of oral E2 valerate from day 25 of the previous cycle until the day before starting stimulation
Study: 34496087
Drug: Nanomicelle curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanomicelle curcumin (CUR) 80 mg
Study: 34496087
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (NS) 1,000 mg
Study: 34496087
Drug: CUR (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUR (80 mg) and NS (1,000 mg)
Study: 34497110
Drug: Ertugliflozin (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (pooled doses)
Study: 32780926
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg over 10 minutes, 0.5 µg/kg/h during surgery, and 1 µg/kg after cardiopulmonary bypass)
Study: 36344766
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg oral nanocrystal formulation for 10 days
Study: 32652024
Drug: 6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/d of long-chain triglycerides (LCT group)
Study: 32652024
Drug: LD +
Normalized name: Children's Tylenol Cold + Flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD + MCT group (1.2 g L-leucine and 20 μg cholecalciferol enriched with 6 g/d of MCTs)
Study: 32326727
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy for 12 weeks
Study: 35534825
Drug: Esketamine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 0.2 mg/kg
Study: 35380740
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg b.i.d.
Study: 35380740
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg b.i.d.
Study: 33214446
Drug: Preoperative hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hepatic and regional arterial chemotherapy (PHRAC) plus adjuvant therapy